Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

BACKGROUND: Skin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion...

詳細記述

保存先:
書誌詳細
出版年:J Immunother Cancer
主要な著者: Leiter, Ulrike, Loquai, Carmen, Reinhardt, Lydia, Rafei-Shamsabadi, David, Gutzmer, Ralf, Kaehler, Katharina, Heinzerling, Lucie, Hassel, Jessica C, Glutsch, Valerie, Sirokay, Judith, Schlecht, Nora, Rübben, Albert, Gambichler, Thilo, Schatton, Kerstin, Pfoehler, Claudia, Franklin, Cindy, Terheyden, Patrick, Haferkamp, Sebastian, Mohr, Peter, Bischof, Lena, Livingstone, Elisabeth, Zimmer, Lisa, Weichenthal, Michael, Schadendorf, Dirk, Meiwes, Andreas, Keim, Ulrike, Garbe, Claus, Becker, Jürgen Christian, Ugurel, Selma
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2020
主題:
Clinical/Translational Cancer Immunotherapy
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7583786/
https://ncbi.nlm.nih.gov/pubmed/33093156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000897
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料